Search

According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the NMDP registry.

In a recent interview, MSK's Dr. Jeffrey Drebin addressed why it’s important for people to keep up with their routine screenings and not put off cancer treatment or surgery.

Sloan Kettering Institute scientists are understanding more about natural killer (NK) cells, which are your allies when it comes to fighting infections and cancer.

Philip W. Kantoff, MD, has been named the new Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). An accomplished leader, physician, researcher, and mentor, Dr. Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School (HMS) since 1987 in a variety of capacities. He formally assumes his new position as George J. Bosl, MD, steps down from his role after 18 years.

Memorial Sloan Kettering Cancer Center (MSK) will award three influential cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the understanding of cancer or are improving the treatment of the disease.

Memorial Sloan Kettering Cancer Center (MSK) announced its recommitment to communities across Long Island today with the dedication of MSK Nassau, a light-filled 114,000-square-foot outpatient cancer treatment facility centrally located along Hempstead Turnpike. MSK’s newest location, and its third on Long Island, will open for patient care on April 8 with more than 180 dedicated medical and professional staff, all of whom are MSK employees.

We love our smartphones, but could they be harming our health? An MSK expert weighs in.